Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034229 | 0.98 | TSHR (0.54) | TSHRGAAKMT2AMEN1THRB | |
| SCHEMBL19666673 | 0.94 | TSHR (0.58) | TSHRGAAKMT2AMEN1THRB | |
| SCHEMBL29264633 | 0.92 | TSHR (0.56) | TSHRGAAKMT2AMEN1THRB | |
| SCHEMBL8741176 | 0.92 | TSHR (0.56) | TSHRGAAKMT2AMEN1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL3728453 | 0.89 | TSHR (0.58) | TSHRGAAKMT2AMEN1THRB | |
| SCHEMBL25196628 | 0.89 | TSHR (0.64) | TSHRGAAKMT2AMEN1LMNA | |
| SCHEMBL16059320 | 0.89 | TSHR (0.64) | TSHRGAAKMT2AMEN1LMNA | |
| SCHEMBL25193436 | 0.89 | TSHR (0.64) | TSHRGAAKMT2AMEN1LMNA | |
| SCHEMBL8368795 | 0.89 | TSHR (0.64) | TSHRGAAKMT2AMEN1LMNA | |
| Di(Hydroxyethyl)Ether SCHEMBL23702411 | 0.88 | TSHR (0.67) | TSHRKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282884-A1 | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | BIOSITE, INC. | 2005-12-22 | — | — | US | disclosed |
| US-6967107-B2 | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | BIOSITE, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050181416-A1 | N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES, AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.) | 2005-08-18 | — | — | US | disclosed |
| US-6887952-B1 | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | BIOSITE, INC. (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282884-A1 | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | ASPH, JMJD7, ASNS | TSHR 3981/4885GAA 737/4885KMT2A 702/4885 |
| US-20050181416-A1 | N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES, AND METHODS FOR THEIR SYNTHESIS AND USE | ASPH, JMJD7, ASNS | TSHR 3981/4885GAA 737/4885KMT2A 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.